Evidence-based guide to vitamin B5: Coenzyme A (CoA) synthesis, steroid hormones, skin repair, pantethine for lipids, and exceptional safety profile.
Pantothenic acid, or vitamin B5, rarely becomes the central topic of discussions about nutrition. It does not have an association as recognizable as vitamin B12 with blood formation, folate with pregnancy, or vitamin D with bone health. Yet at the level of cellular biochemistry, B5 is integrated into one of the most fundamental systems of human metabolism. The body uses pantothenic acid to synthesize coenzyme A, a molecule through which fatty acid oxidation, pyruvate metabolism, the tricarboxylic acid cycle, lipid and cholesterol synthesis, heme formation, acetylcholine production, and a vast number of other reactions are routed.
The vitamin’s name comes from the Greek word pantothen, meaning “from everywhere” or “all around.” It is unusually appropriate: pantothenic acid is widely distributed both throughout living organisms and across the food supply. This ubiquity explains the paradox of vitamin B5. On the one hand, cellular metabolism is literally impossible without it. On the other, isolated dietary deficiency in humans is so rare that much of what we know about its severe manifestations comes from older experimental studies, extreme malnutrition, and rare genetic disorders. The NIH and modern nutritional reviews emphasize that an ordinary mixed diet almost always provides sufficient pantothenic acid.
For this reason, vitamin B5 illustrates especially well an important distinction that is often lost in the supplement industry: a nutrient can be absolutely indispensable to metabolism while still rarely requiring additional supplementation in a healthy person.
Free pantothenic acid is not itself a universal catalyst of metabolic reactions. Its main biological value lies in serving as a precursor for the synthesis of coenzyme A, CoA, and 4′-phosphopantetheine, the functional group of acyl carrier protein involved primarily in fatty acid synthesis.
CoA synthesis proceeds through a sequence of five enzymatic steps. First, pantothenate is phosphorylated to form 4′-phosphopantothenate. This reaction is catalyzed by pantothenate kinases and represents one of the major regulated steps of the entire pathway. In humans, the catalytically active pantothenate kinases are PANK1, PANK2, and PANK3. An important correction is needed here: although PANK4 belongs to the same protein family, human PANK4 does not possess normal pantothenate kinase activity and is considered a pseudoenzyme with a different regulatory function.
In the next steps, cysteine is added to the molecule, a carboxyl group is removed, and 4′-phosphopantetheine is formed. An adenylate moiety is then added to generate dephospho-CoA, which is converted into functional coenzyme A in the final reaction. In mammals, the last two enzymatic activities are combined within a bifunctional CoA synthase. The resulting molecule contains a reactive terminal thiol group, —SH, capable of temporarily binding acyl groups.
This chemical feature defines nearly everything that follows. When an acetyl group binds to CoA, acetyl-CoA is formed; when a longer fatty acid is attached, the corresponding acyl-CoA is generated. The thioester bond has a high group-transfer potential, so CoA does not act merely as a passive carrier. It activates the bound molecule and makes it suitable for the next biochemical reaction.
The result is a kind of intracellular logistics system: a carbon-containing group is attached to CoA, transported into the appropriate metabolic pathway, released, and the coenzyme can then be reused.
Modern reviews place the scale of this system very high. CoA and its derivatives participate in the activity of a substantial proportion of cellular enzymes, while the pools of free CoA and acyl-CoA are dynamically regulated according to nutritional status, fasting, demand for fatty acid oxidation, and biosynthetic activity.
To understand the importance of vitamin B5, it is more useful to look at acetyl-CoA than at the vitamin in isolation.
Carbohydrates are broken down through glycolysis to pyruvate, and the pyruvate dehydrogenase complex converts pyruvate into acetyl-CoA. Fatty acids are degraded through β-oxidation, releasing two-carbon fragments in the form of acetyl-CoA during each cycle. The carbon skeletons of several amino acids can also enter metabolism through acetyl-CoA, acetoacetate, or related intermediates.
Acetyl-CoA then condenses with oxaloacetate to form citrate, initiating the tricarboxylic acid cycle. The cycle itself does not directly “produce dozens of ATP molecules.” Its major energetic role is to generate reduced NADH and FADH₂, whose electrons are then transferred to the mitochondrial respiratory chain for ATP synthesis. This distinction matters because simplified diagrams often blur the Krebs cycle together with the oxidative phosphorylation that follows it.
Acetyl-CoA is also essential for building molecules rather than merely breaking nutrients down. When energy is abundant, citrate can leave the mitochondrion and return acetyl units to the cytosol, where they are used to generate malonyl-CoA and initiate fatty acid synthesis. This process involves the second major B5-derived component: the 4′-phosphopantetheine “arm” of acyl carrier protein, which physically shuttles the growing fatty acid chain between catalytic sites of the fatty acid synthase complex.
The main direct product of human fatty acid synthase is palmitate. Stearate, oleate, and other longer-chain or unsaturated fatty acids are produced later through elongation and desaturation. It would therefore be too simplistic to say that fatty acid synthase itself directly produces palmitic, stearic, and oleic acids all at once.
Acetyl-CoA is also the starting point of the mevalonate pathway. Through HMG-CoA and mevalonate, the cell generates not only cholesterol but also a broad range of isoprenoid compounds needed for the synthesis of steroid hormones, bile acids, ubiquinone—coenzyme Q10—dolichols, and protein prenylation.
Another CoA derivative, succinyl-CoA, reacts with glycine during the first regulated step of porphyrin synthesis. This pathway ultimately produces heme, a component of hemoglobin, myoglobin, and numerous cytochromes.
Finally, acetyl-CoA acts as the direct donor of the acetyl group used to synthesize acetylcholine: choline acetyltransferase transfers this group to choline in cholinergic neurons. Here, the relationship is genuinely direct. Without available acetyl-CoA, acetylcholine synthesis cannot proceed normally.
Vitamin B5 therefore cannot be tied to one organ or one physiological function. Through CoA, it sits at the center of cellular metabolic architecture.
Vitamin B5 is frequently marketed as a nutrient “for the adrenal glands,” and high doses of pantothenate are often included in so-called adrenal support formulas. At first glance, the biochemical explanation seems convincing: steroid hormones are synthesized from cholesterol, cholesterol derives from acetyl-CoA, acetyl-CoA requires coenzyme A, and coenzyme A requires pantothenic acid. Therefore, B5 is necessary for cortisol synthesis.
At the level of basic physiology, this is true. If an organism is deprived of pantothenate so severely that CoA synthesis becomes impaired, normal steroid metabolism will also be affected. Older animal experiments showed that severe pantothenic acid deficiency could disrupt adrenal cortex function, while supplementation could modify corticosteroid secretion. Similar effects have also been observed in later animal studies.
But this is exactly where a line must be drawn between physiological necessity and clinical benefit from supplementation.
There is no convincing evidence that ordinary chronic psychological stress gradually “uses up CoA,” causes B5 deficiency, or exhausts otherwise healthy adrenal glands in a way that can be corrected by taking hundreds of milligrams of pantothenate. Nor is there evidence that additional B5 in a person with normal nutritional status meaningfully increases the adrenal glands’ ability to produce cortisol.
Moreover, “adrenal fatigue” itself is not recognized as a valid medical diagnosis in contemporary endocrinology. The Endocrine Society states that there is no scientific evidence for a condition in which chronic life stress “wears out” the adrenal glands and reduces their ability to produce hormones. True adrenal insufficiency does exist, but it is a specific disease with known causes, diagnostic criteria, and laboratory tests.
Vitamin B5 is therefore connected to steroidogenesis through the fundamental biochemistry of CoA and cholesterol, but this does not imply a need to “support the adrenal glands” with high-dose supplementation during stress. The formula “stress depletes B5, B5 restores the adrenals” goes far beyond the available evidence.
The story is quite different with dexpanthenol.
Dexpanthenol is the alcohol analogue of pantothenic acid and is converted into pantothenate after entering tissues. Topical use of dexpanthenol has become one of the best-supported clinical applications related to vitamin B5.
On the skin surface, dexpanthenol acts both as a moisturizing agent and as a compound associated with epidermal repair. Clinical and experimental studies show increased hydration of the stratum corneum, reduced transepidermal water loss, and beneficial effects on restoration of barrier function after superficial skin injury. In studies following laser procedures and other controlled forms of skin damage, 5% dexpanthenol formulations accelerated early re-epithelialization compared with control sites or base preparations.
But even here, a real effect should not be transformed into a universal regenerative theory. Dexpanthenol is best studied as a treatment for dry, irritated, or superficially damaged skin and as part of post-procedure care. This does not mean it can independently treat deep burns, chronic trophic ulcers, or radiation injury without appropriate primary treatment.
Molecular studies do show changes in the expression of genes involved in tissue repair, inflammatory responses, and barrier function. However, the common claim that “panthenol activates synthesis of type I and III collagen and elastin” is stronger than the clinical evidence supports. It is more accurate to speak about support of repair processes and epidermal barrier recovery rather than a proven systemic “collagen stimulator.”
The distinction between topical dexpanthenol and oral vitamin B5 is often lost in advertising. The fact that a 5% ointment can help repair a damaged epidermal barrier does not mean that swallowing 500 mg of pantothenate will produce an equivalent effect in the skin.
Unlike many other vitamins, pantothenic acid does not have a formal Recommended Dietary Allowance based on a precisely established average requirement. The reason is straightforward: clinical deficiency is exceptionally rare, and the available evidence is insufficient to determine a precise minimum physiological requirement.
Instead, recommendations use the category Adequate Intake, or AI. In the U.S. system, adults are assigned 5 mg per day, pregnant women 6 mg, and breastfeeding women 7 mg. European estimates are similar, with EFSA also suggesting about 5 mg per day for adults. In children, recommended intake gradually rises from roughly 1.7–1.8 mg in infancy to about 5 mg during adolescence.
Once again, the name “pantothenic” is appropriate: the vitamin is found almost everywhere. Sources include meat and organ meats, poultry, eggs, dairy products, mushrooms, avocados, potatoes, broccoli, legumes, whole grains, peanuts, and sunflower seeds. The practical issue is therefore usually not finding a unique “superfood” source, but maintaining overall dietary variety.
In ordinary foods, B5 is present not only as free pantothenic acid. A substantial proportion exists as part of CoA, acyl-CoA, and phosphopantetheine-containing compounds. In the digestive tract, these molecules are gradually hydrolyzed until free pantothenate is released and becomes available for absorption.
The main intestinal transporter is the sodium-dependent multivitamin transporter, SMVT, encoded by SLC5A6. This transporter is notable because it carries not only pantothenate but also biotin. Experimental systems also show transport of lipoate. At physiological concentrations, B5 is absorbed primarily through this saturable mechanism, while at very high concentrations passive transport contributes more.
The bioavailability of B5 from a mixed diet has not been characterized perfectly; modern reviews suggest approximate values in the range of 40–60%. Some vitamin is lost during industrial processing and food preparation, particularly when outer layers of grains are removed or when the vitamin leaches into cooking water. But universal statements such as “cooking always destroys 50–75% of vitamin B5” should be avoided because losses vary greatly by food and processing method.
Isolated pantothenic acid deficiency is so uncommon that its clinical picture is difficult to separate from deficiencies of other nutrients.
Classic experimental studies from the mid-20th century deliberately induced B5 deficiency in volunteers using severely restricted diets and, in some cases, vitamin antagonists. Under those conditions, researchers described fatigue, irritability, sleep disturbances, gastrointestinal symptoms, paresthesias, and burning sensations in the hands and feet. Modern NIH materials list numbness and burning of the hands and feet, extreme fatigue, headache, irritability, restlessness, impaired sleep, abdominal pain, nausea, vomiting, diarrhea, and loss of appetite among possible symptoms of severe deficiency.
None of these symptoms, however, is specific to B5 alone.
The most famous association is burning feet syndrome. It was described in prisoners of war who experienced profound nutritional deprivation during World War II and was later linked to pantothenic acid deficiency, with some similar sensory symptoms reproduced experimentally. Yet those prisoners did not have isolated B5 deficiency. They suffered simultaneous calorie, protein, and multiple micronutrient deficiencies. Follow-up studies of former prisoners did document persistent peripheral neuropathies, including burning-feet-type syndromes, but retrospectively assigning a single vitamin cause is impossible.
Burning feet should therefore not be regarded as a pathognomonic sign of pantothenic acid deficiency. The symptom has a broad differential diagnosis, ranging from diabetic and alcohol-related neuropathy to deficiencies of other vitamins, compressive neuropathies, thyroid disease, toxic exposures, and erythromelalgia.
Clinically significant B5 deficiency today is more plausible in the setting of profound generalized malnutrition, severe malabsorption, extremely restrictive diets, or long-term artificial nutrition without adequate vitamin supplementation. Even then, B5 is usually not the only nutrient that is lacking.
For the same reason, nonspecific symptoms such as morning fatigue, orthostatic instability, or “stress exhaustion” are not enough to diagnose pantothenate deficiency.
Assessment of B5 status is far less standardized than testing for iron, vitamin B12, or folate.
Pantothenic acid can be measured in blood, but concentrations are influenced by recent intake and do not have universally validated thresholds for diagnosing tissue deficiency. Twenty-four-hour urinary excretion of pantothenate is considered a more informative marker because it reflects recent intake reasonably well.
A modern review prepared for the Nordic Nutrition Recommendations notes that urinary excretion below 1 mg per day is considered low, as is a concentration below approximately 1 μmol/L in whole blood, but it also emphasizes an important limitation: population data remain sparse and rigorously validated cutoffs for adequacy and deficiency do not exist. These values therefore should not be treated as absolute diagnostic thresholds.
In practice, suspicion of clinically meaningful deficiency should arise primarily from the context—severe malnutrition, malabsorption, artificial nutrition, or multiple concurrent deficiencies—rather than from trying to explain nonspecific fatigue in a person eating a normal mixed diet.
It is even less appropriate to use salivary cortisol or so-called adrenal fatigue profiles to diagnose B5 deficiency. These tests do not measure pantothenic acid status.
A completely different story is pantothenate kinase-associated neurodegeneration, or PKAN, a rare autosomal recessive disorder within the group of neurodegeneration with brain iron accumulation.
PKAN is caused by pathogenic variants in the PANK2 gene, which encodes one of the pantothenate kinases. The disease disrupts the first regulated step of CoA biosynthesis in cellular compartments where PANK2 is especially important. This leads to abnormalities in CoA homeostasis and lipid metabolism, mitochondrial dysfunction, oxidative stress, and pathological iron accumulation predominantly in the globus pallidus. The mechanism is more complicated than the simple formula “CoA synthesis stops, cysteine accumulates, and iron is trapped.” Modern work points to multiple interconnected metabolic disturbances.
Brain MRI often shows the well-known eye-of-the-tiger sign: a central area of high signal within the globus pallidus surrounded by hypointensity related to iron deposition. But the word “pathognomonic” should still be used cautiously. The sign is highly characteristic of PKAN but may be absent at certain disease stages and is not absolutely specific. Final diagnosis relies on the clinical picture, neuroimaging, and genetic confirmation.
Clinically, PKAN can cause progressive dystonia, rigidity, dysarthria, spasticity, and other movement disorders. Some patients also develop neuropsychiatric symptoms and retinal degeneration.
One of the most informative aspects of PKAN is that it cannot simply be “treated with vitamin B5.” If PANK2 function is severely impaired, merely increasing the amount of its substrate does not repair the enzymatic defect. Yet the situation is more nuanced than saying pantothenate is always useless. Some mutations preserve residual enzyme activity, so high doses of pantothenate might theoretically help a subset of patients. Modern recommendations allow for therapeutic trials in selected cases, although most patients with classic PKAN do not show meaningful improvement and controlled evidence remains limited. Meanwhile, researchers are studying ways to bypass the blocked step of CoA synthesis, including 4′-phosphopantetheine and related metabolic strategies.
PKAN therefore demonstrates not how useful ordinary B5 supplements are, but how critically important the tightly regulated intracellular synthesis of CoA is.
Supplements may contain either ordinary calcium D-pantothenate or pantethine. They are often presented as two versions of the same vitamin, with pantethine described as a “more active” form that automatically bypasses all metabolic limitations of B5.
Calcium pantothenate is indeed a stable salt of pantothenic acid and is widely used in multivitamins. After absorption, pantothenate enters the normal pathway of CoA biosynthesis.
Pantethine is the disulfide form of pantetheine and is metabolically closer to later intermediates of the pathway. Alternative ways of using pantethine when PANK activity is impaired have been demonstrated experimentally, but human metabolism cannot be summarized by saying that “pantethine enters the cell and completely bypasses PANK.” Extracellular pantetheine is actively broken down by vanin-family pantetheinases back into pantothenate and cysteamine, making the fate of these compounds much more complex.
Pantethine does, however, have a separate and interesting pharmacological history: effects on the lipid profile.
In a randomized controlled trial of 120 people at low to moderate cardiovascular risk, 600 mg of pantethine per day, later increased to 900 mg, produced an additional reduction in total cholesterol of about 3%, LDL cholesterol of roughly 4%, and apolipoprotein B of about 5% compared with diet and placebo. Another small study reported an approximately 11% reduction in LDL cholesterol from baseline.
The effect therefore appears real, but it cannot be described as a guaranteed 10–20% reduction in LDL and a 20–35% decrease in triglycerides in every patient. Results vary between studies and according to baseline lipid status, the number of modern high-quality trials is small, and there is no evidence that pantethine reduces myocardial infarction, stroke, or mortality.
The NIH’s current assessment is appropriately cautious: research on pantethine and cholesterol or triglycerides appears promising, but available data remain insufficient to define its clinical role confidently.
Pantethine should therefore not be placed on the same level as statins, ezetimibe, PCSK9 inhibitors, or other therapies with established effects on cardiovascular outcomes. At most, current evidence supports the possibility of a modest adjunctive lipid-modifying effect.
There is even less justification for recommending pantethine as standard treatment for metabolic dysfunction-associated steatotic liver disease or as a universal substitute for statins in people with statin intolerance.
Pantothenic acid has very low known toxicity. Neither the U.S. Dietary Reference Intake system nor European authorities have established a tolerable upper intake level, largely because convincing toxic effects from ordinary oral intake have not been identified.
The NIH notes that very large doses, for example around 10,000 mg per day, may cause gastrointestinal upset and diarrhea. But that is not the same as proving that 10–15 grams per day are completely safe during years of use. Absence of identified toxicity and absence of sufficient evidence to establish an upper limit are not quite the same thing.
The statement that “even 15 grams is entirely safe and causes no organ toxicity” therefore extends beyond the evidence.
Proposed drug interactions also need to be treated carefully. It is sometimes claimed that B5 can intensify the effects of donepezil, rivastigmine, or other cholinesterase inhibitors by increasing acetylcholine production. The biochemical hypothesis is understandable, but clinically meaningful interaction has not been demonstrated. Current NIH information states that no clinically significant drug interactions are known for pantothenic acid.
The same applies to tetracyclines. Calcium pantothenate contains calcium, but the amount of elemental calcium in ordinary vitamin doses is small, and there is no good reason to automatically apply the interaction rules for full-dose calcium supplements without direct evidence.
The relationship with biotin is more interesting. Pantothenate and biotin do share the same SMVT transporter, and pantothenic acid can compete with biotin transport in experimental systems. But this does not yet allow us to conclude that gram-level B5 supplementation routinely causes clinically important biotin deficiency and hair loss in humans. The mechanism is biologically plausible, but clinical evidence is insufficient to make compensatory biotin supplementation mandatory whenever high-dose B5 is used.
For most healthy people, the answer is rather unremarkable: a separate supplement is usually unnecessary.
If the diet already provides around 5 mg of pantothenic acid per day, increasing intake to 100, 500, or 1,000 mg does not mean that the body will proportionally increase its CoA concentration, Krebs cycle activity, energy production, cortisol synthesis, or resistance to stress. Cellular CoA pools are governed by a complex system of feedback regulation, enzyme expression, synthesis and degradation rates, availability of other substrates, and tissue-specific demand. CoA is not a storage tank that can simply be “filled up” by pouring in more vitamin.
This is particularly important in relation to fatigue. Weakness, impaired performance, insomnia, and irritability can indeed occur during experimentally induced B5 deficiency, but they are so nonspecific that the reverse conclusion is invalid: being tired does not mean a person is deficient in B5.
Nor can high doses be justified simply by invoking “stress.” Animal experiments involving the adrenal glands are interesting for understanding physiology, but they have not translated into a proven treatment for stress-related states in humans.
Skin health also requires separating two entirely different interventions. Topical dexpanthenol has a reasonable evidence base for moisturizing and supporting recovery of a superficially damaged epidermal barrier. High-dose oral pantothenate does not have a comparable evidence base for “skin regeneration,” stimulation of collagen synthesis, or general rejuvenation.
Gram-level doses of B5 are also periodically promoted for acne treatment. Small studies exist, but the evidence is not sufficient for high-dose pantothenic acid to be included in standard dermatology guidelines, and the hypothesis that acne results from “CoA deficiency during fatty acid metabolism” is not considered an established mechanism of the disease.
Pantothenic acid is a particularly good example of how easily a logical error can arise.
A completely correct biochemical chain can be constructed:
B5 is required for CoA. CoA is required for acetyl-CoA. Acetyl-CoA is involved in energy metabolism, cholesterol synthesis, and acetylcholine production. Cholesterol is needed for steroid hormones. Therefore, without B5 normal energy metabolism, nervous system function, and steroidogenesis are impossible.
All of this is true.
But the next conclusion—“therefore extra B5 increases energy, improves nervous system function, and boosts the adrenal glands”—does not follow from the previous statements.
Enzymes and cofactors operate within ranges of saturation. Once a system already has enough substrate, supplying more does not necessarily accelerate the reaction. This is why the clinical importance of a nutrient is greatest when it is deficient and often falls sharply once adequate status has been achieved.
The same logic explains why rare, severe B5 deficiency can produce diverse metabolic and neurological symptoms, while an additional hundred milligrams may have no noticeable effect at all in a well-nourished person.
Vitamin B5 truly lies at the foundation of an enormous number of metabolic pathways. But occupying a central position on a biochemical diagram does not make a high-dose supplement a universal therapy.
For a healthy person, the main strategy is very simple: a varied diet almost always provides sufficient pantothenic acid. There is usually no need to count every milligram of B5, and an AI of 5 mg is easily achieved through a combination of ordinary foods.
In severe malnutrition, malabsorption, or long-term artificial nutrition, B5 should be considered as part of overall micronutrient status rather than as an isolated “pantothenate syndrome.” Burning sensations in the feet require a proper evaluation for causes of peripheral neuropathy and should not automatically lead to a diagnosis of vitamin B5 deficiency.
True adrenal insufficiency requires endocrinological diagnosis and appropriate hormone replacement therapy, not “adrenal support” with pantothenate.
In dermatology, 5% dexpanthenol can be useful for supporting epidermal barrier recovery and caring for superficially damaged or irritated skin. In dyslipidemia, pantethine remains scientifically interesting as an adjunct with a modest lipid-lowering effect, but it is not a substitute for treatments proven to reduce cardiovascular risk.
And in PKAN, the issue is not dietary B5 deficiency at all but a genetic disturbance in the regulated synthesis of CoA—an example of just how complex this system is and why simply increasing the amount of the starting vitamin is often insufficient.
Ultimately, four different levels should be kept separate when discussing vitamin B5: the physiological necessity of pantothenic acid, the body’s actual vitamin status, the pharmacology of its derivatives, and the clinical outcome of a specific intervention. These levels are related, but they are not interchangeable.
Pantothenic acid is an essential precursor of coenzyme A and 4′-phosphopantetheine and, through them, one of the fundamental components of cellular energy, lipid, and biosynthetic metabolism. Severe deficiency can impair nervous system function and other organs, but in people eating an ordinary varied diet such deficiency is exceptionally rare. The main practical value of vitamin B5 therefore lies not in megadoses “for energy” or “for the adrenal glands,” but in adequate nutritional intake and in the rational use of specific derivatives—most notably dexpanthenol and, to a much more limited extent, pantethine—where their effects have actually been studied.
This material is for educational purposes only and does not replace medical diagnosis, treatment, or individualized medical advice.
Yes, adrenal cortical tissue maintains a rich CoA pool to produce glucocorticoids like cortisol. Adequate B5 prevents substrate limitation during sustained endocrine demand.
Calcium pantothenate is the standard nutrient form for correcting deficiency, whereas pantethine actively inhibits hepatic HMG-CoA reductase and acetyl-CoA carboxylase, favorably modifying lipid profiles.